MDGL

SEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 24

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 197,746

F16 · kind: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026.

F26 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $546.28 to $546.56, inclusive.

SEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 23

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 197,866

F16 · kind: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026.

F25 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $544.38 to $545.32, inclusive.

SEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 22

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 198,627

F16 · kind: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026.

F24 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $543.27 to $544.20, inclusive.

SEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 21

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 200,166

F16 · kind: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026.

F23 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $542.11 to $543.02, inclusive.

SEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 20

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 201,368

F16 · kind: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026.

F22 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $541.00 to $541.73, inclusive.

SEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 19

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 201,736

F16 · kind: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026.

F21 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $539.97 to $540.90, inclusive.

SEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 18

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 202,423

F16 · kind: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026.

F20 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $537.235 to $538.00, inclusive.

SEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 17

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 202,583

F16 · kind: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026.

F19 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $535.52 to $536.02, inclusive.

SEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 16

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 202,801

F16 · kind: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026.

F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $533.76 to $534.48, inclusive.

SEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 15

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 202,907

F16 · kind: These sales were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 5, 2026.

F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $532.76 to $533.64, inclusive.

SEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 14

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 202,967

F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $542.42 to $542.68, inclusive.

SEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 13

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 203,127

F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $541.29 to $542.27, inclusive.

SEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 12

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 203,489

F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $539.86 to $540.47, inclusive.

SEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 11

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 203,994

F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $538.86 to $539.83, inclusive.

SEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 10

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 204,209

F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $537.70 to $538.65, inclusive.

SEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 9

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 204,729

F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $536.64 to $537.56, inclusive.

SEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 8

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 205,369

F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $535.64 to $536.45, inclusive.

SEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 7

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 206,409

F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $534.63 to $535.62, inclusive.

SEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 6

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 207,053

F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $533.58 to $534.57, inclusive.

SEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 5

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 207,449

F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $532.57 to $533.29, inclusive.

SEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 4

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 207,961

F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $531.57 to $532.28, inclusive.

SEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 3

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 208,329

F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $529.64 to $530.48, inclusive.

SEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 2

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 208,851

F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $528.54 to $529.51, inclusive.

SEC source: 0001628280-26-061581 · wk-form4_1789160228.xml · nonDerivative · entry 1

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 209,198

F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $527.49 to $528.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

SEC source: 0001628280-26-058256 · wk-form4_1787257250.xml · nonDerivative · entry 1

Kelley Shannon T · CIK 0002034056 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,474

F1 · kind: This sale represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was automatic and not at the discretion of the Reporting Person.

SEC source: 0001628280-26-057751 · wk-form4_1787087423.xml · derivative · entry 2

REED JOHN C · CIK 0001181561 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,078

Underlying: Common Stock · 1,078 shares

Expires 2036-08-15

F2 · derivative.exercise_date: The option vests as to 50% of the shares on the first anniversary of the date of grant (August 15, 2027), and, thereafter, 12.5% of the shares shall vest on the last day of each successive three-month period for four successive three-month periods, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0001628280-26-057751 · wk-form4_1787087423.xml · nonDerivative · entry 1

REED JOHN C · CIK 0001181561 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 647

F1 · kind: Represents a grant of restricted stock units which vest as to 50% of the shares on each of August 15, 2027 and August 15, 2028, provided the Reporting Person continues in service with the Issuer on each such date.

SEC source: 0001628280-26-048919 · wk-form4_1784596610.xml · nonDerivative · entry 11

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 209,329

F2 · kind: The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person.

F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $555.00 to $555.10, inclusive.

SEC source: 0001628280-26-048919 · wk-form4_1784596610.xml · nonDerivative · entry 10

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 209,609

F2 · kind: The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person.

SEC source: 0001628280-26-048919 · wk-form4_1784596610.xml · nonDerivative · entry 9

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 209,610

F2 · kind: The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person.

F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $549.70 to $550.24, inclusive.

SEC source: 0001628280-26-048919 · wk-form4_1784596610.xml · nonDerivative · entry 8

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 209,763

F2 · kind: The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $548.42 to $549.39, inclusive.

SEC source: 0001628280-26-048919 · wk-form4_1784596610.xml · nonDerivative · entry 7

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 209,810

F2 · kind: The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $547.40 to $548.29, inclusive.

SEC source: 0001628280-26-048919 · wk-form4_1784596610.xml · nonDerivative · entry 6

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 210,490

F2 · kind: The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $546.37 to $547.35, inclusive.

SEC source: 0001628280-26-048919 · wk-form4_1784596610.xml · nonDerivative · entry 5

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 210,759

F2 · kind: The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $545.31 to $546.29, inclusive.

SEC source: 0001628280-26-048919 · wk-form4_1784596610.xml · nonDerivative · entry 4

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 211,034

F2 · kind: The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $544.31 to $545.28, inclusive.

SEC source: 0001628280-26-048919 · wk-form4_1784596610.xml · nonDerivative · entry 3

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 211,579

F2 · kind: The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $543.26 to $544.25, inclusive.

SEC source: 0001628280-26-048919 · wk-form4_1784596610.xml · nonDerivative · entry 2

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 211,689

F2 · kind: The sale reported on this line represents the number of shares sold by the Issuer on behalf of the Reporting Person to cover certain tax withholding obligations in connection with the Reporting Person earning 50,000 shares of common stock as described in Footnote 1 above. This sale was automatic and not at the discretion of the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $542.22 to $543.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

SEC source: 0001628280-26-048919 · wk-form4_1784596610.xml · derivative · entry 12

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F12 · derivative.exercise_price: On September 11, 2023, the Reporting Person was granted a one-time sign-on award of Performance Restricted Stock Units with a target award of 50,000 shares of common stock that could be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person was eligible to earn up to 300% of the target award. Following the achievement of the first hurdle in February 2025, the second hurdle in December 2025 and the third and final hurdle reported on this line, all performance hurdles have been achieved. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the Performance Restricted Stock Units.

F12 · derivative.exercise_date: On September 11, 2023, the Reporting Person was granted a one-time sign-on award of Performance Restricted Stock Units with a target award of 50,000 shares of common stock that could be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person was eligible to earn up to 300% of the target award. Following the achievement of the first hurdle in February 2025, the second hurdle in December 2025 and the third and final hurdle reported on this line, all performance hurdles have been achieved. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the Performance Restricted Stock Units.

F12 · derivative.expiration_date: On September 11, 2023, the Reporting Person was granted a one-time sign-on award of Performance Restricted Stock Units with a target award of 50,000 shares of common stock that could be earned upon the achievement of significant sustained stock price appreciation hurdles over a five-year period. The Reporting Person was eligible to earn up to 300% of the target award. Following the achievement of the first hurdle in February 2025, the second hurdle in December 2025 and the third and final hurdle reported on this line, all performance hurdles have been achieved. See the Issuer's Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 for additional information about the Performance Restricted Stock Units.

SEC source: 0001628280-26-048919 · wk-form4_1784596610.xml · nonDerivative · entry 1

Sibold William John · CIK 0001518611 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 211,829

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: On July 17, 2026, the Reporting Person earned 50,000 shares of common stock following the achievement of the performance and service conditions of the Performance Restricted Stock Units described in Footnote 12. Pursuant to the terms of the award, certain of these shares were sold to cover certain tax withholding obligations as described in Footnote 2 below. The Issuer is irrevocably obligated to issue the remaining shares to the Reporting Person on September 8, 2029, the sixth anniversary of the commencement of his employment with the Issuer.

F1 · price: On July 17, 2026, the Reporting Person earned 50,000 shares of common stock following the achievement of the performance and service conditions of the Performance Restricted Stock Units described in Footnote 12. Pursuant to the terms of the award, certain of these shares were sold to cover certain tax withholding obligations as described in Footnote 2 below. The Issuer is irrevocably obligated to issue the remaining shares to the Reporting Person on September 8, 2029, the sixth anniversary of the commencement of his employment with the Issuer.

SEC source: 0001193125-26-275800 · ownership.xml · derivative · entry 4

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,532

Underlying: Common Stock · 1,532 shares

Expires 2036-06-17

F10 · shares: Includes 766 Stock Options granted by the Issuer to each of Julian C. Baker and Dr. Cheong on June 17, 2026, pursuant to the 2026 Plan. The Stock Options have a strike price of $499.86, fully vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, subject to the applicable director's continuous service with the Issuer through such vesting date, and expire 10 years from the date of grant.

F10 · derivative.exercise_date: Includes 766 Stock Options granted by the Issuer to each of Julian C. Baker and Dr. Cheong on June 17, 2026, pursuant to the 2026 Plan. The Stock Options have a strike price of $499.86, fully vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, subject to the applicable director's continuous service with the Issuer through such vesting date, and expire 10 years from the date of grant.

F3 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker and Dr. Cheong do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified stock options exercisable solely into Common Stock ("Stock Options") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F4 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F5 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F6 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F7 · ownership.nature: The acquisitions of the RSUs and Stock Options reported on this form represent grants to each of Julian C. Baker and Dr. Cheong of 454 RSUs on Table I and 766 Stock Options on Table II. These grants, totaling 908 RSUs and 1,532 Stock Options for Julian C. Baker and Dr. Cheong in the aggregate, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F9 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0001193125-26-275800 · ownership.xml · derivative · entry 3

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,532

Underlying: Common Stock · 1,532 shares

Expires 2036-06-17

F10 · shares: Includes 766 Stock Options granted by the Issuer to each of Julian C. Baker and Dr. Cheong on June 17, 2026, pursuant to the 2026 Plan. The Stock Options have a strike price of $499.86, fully vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, subject to the applicable director's continuous service with the Issuer through such vesting date, and expire 10 years from the date of grant.

F10 · derivative.exercise_date: Includes 766 Stock Options granted by the Issuer to each of Julian C. Baker and Dr. Cheong on June 17, 2026, pursuant to the 2026 Plan. The Stock Options have a strike price of $499.86, fully vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, subject to the applicable director's continuous service with the Issuer through such vesting date, and expire 10 years from the date of grant.

F2 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options (as defined below) reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker and Dr. Cheong do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified stock options exercisable solely into Common Stock ("Stock Options") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F4 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F5 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F6 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F7 · ownership.nature: The acquisitions of the RSUs and Stock Options reported on this form represent grants to each of Julian C. Baker and Dr. Cheong of 454 RSUs on Table I and 766 Stock Options on Table II. These grants, totaling 908 RSUs and 1,532 Stock Options for Julian C. Baker and Dr. Cheong in the aggregate, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

SEC source: 0001193125-26-275800 · ownership.xml · nonDerivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 1,948,876

F1 · shares: Includes 454 restricted stock units (each an "RSU") payable solely in common stock ("Common Stock") granted by Madrigal Pharmaceuticals, Inc. (the "Issuer") to each of Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP"), and Dr. Raymond Cheong, a full-time employee of Baker Bros. Advisors LP (the "Adviser"), on June 17, 2026, pursuant to the Issuer's 2026 Stock Plan (the "2026 Plan"). The RSUs fully vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, subject to the applicable director's continuous service with the Issuer through such vesting date. Julian C. Baker and Dr. Cheong serve on the board of directors of the Issuer (the "Board") as representatives of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F3 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker and Dr. Cheong do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified stock options exercisable solely into Common Stock ("Stock Options") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F4 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F5 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F6 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F7 · ownership.nature: The acquisitions of the RSUs and Stock Options reported on this form represent grants to each of Julian C. Baker and Dr. Cheong of 454 RSUs on Table I and 766 Stock Options on Table II. These grants, totaling 908 RSUs and 1,532 Stock Options for Julian C. Baker and Dr. Cheong in the aggregate, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F8 · ownership.nature: Includes beneficial ownership of 3,825 shares of Common Stock received from vested RSUs each previously granted to Julian C. Baker and Dr. Cheong in their capacity as directors of the Issuer.

F9 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0001193125-26-275800 · ownership.xml · nonDerivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

BAKER FELIX · CIK 0001087940 · Director

BAKER JULIAN · CIK 0001087939 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 203,721

F1 · shares: Includes 454 restricted stock units (each an "RSU") payable solely in common stock ("Common Stock") granted by Madrigal Pharmaceuticals, Inc. (the "Issuer") to each of Julian C. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP"), and Dr. Raymond Cheong, a full-time employee of Baker Bros. Advisors LP (the "Adviser"), on June 17, 2026, pursuant to the Issuer's 2026 Stock Plan (the "2026 Plan"). The RSUs fully vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, subject to the applicable director's continuous service with the Issuer through such vesting date. Julian C. Baker and Dr. Cheong serve on the board of directors of the Issuer (the "Board") as representatives of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F2 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I and the Stock Options (as defined below) reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F3 · ownership.nature: Pursuant to the policies of the Adviser, Julian C. Baker and Dr. Cheong do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified stock options exercisable solely into Common Stock ("Stock Options") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Stock Options, RSUs and any Common Stock acquired upon the exercise of Stock Options or vesting of RSUs (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F4 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds or for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds or for the benefit of the Funds.

F5 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F6 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options, RSUs and any Common Stock received as a result of the exercise of Stock Options or vesting of RSUs.

F7 · ownership.nature: The acquisitions of the RSUs and Stock Options reported on this form represent grants to each of Julian C. Baker and Dr. Cheong of 454 RSUs on Table I and 766 Stock Options on Table II. These grants, totaling 908 RSUs and 1,532 Stock Options for Julian C. Baker and Dr. Cheong in the aggregate, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F8 · ownership.nature: Includes beneficial ownership of 3,825 shares of Common Stock received from vested RSUs each previously granted to Julian C. Baker and Dr. Cheong in their capacity as directors of the Issuer.

SEC source: 0001628280-26-044346 · wk-form4_1781814204.xml · derivative · entry 3

Taub Rebecca · CIK 0001423898 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 766

Underlying: Common Stock · 766 shares

Expires 2036-06-17

F3 · derivative.exercise_date: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.

SEC source: 0001628280-26-044346 · wk-form4_1781814204.xml · nonDerivative · entry 1

Taub Rebecca · CIK 0001423898 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 452,667

F1 · kind: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.

SEC source: 0001628280-26-044340 · wk-form4_1781814108.xml · derivative · entry 2

Levy Richard S · CIK 0001454983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 766

Underlying: Common Stock · 766 shares

Expires 2036-06-17

F2 · derivative.exercise_date: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.

SEC source: 0001628280-26-044340 · wk-form4_1781814108.xml · nonDerivative · entry 1

Levy Richard S · CIK 0001454983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,469

F1 · kind: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.

SEC source: 0001628280-26-044325 · wk-form4_1781813955.xml · derivative · entry 2

FOUSE JACQUALYN A · CIK 0001405288 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 766

Underlying: Common Stock · 766 shares

Expires 2036-06-17

F2 · derivative.exercise_date: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.

SEC source: 0001628280-26-044325 · wk-form4_1781813955.xml · nonDerivative · entry 1

FOUSE JACQUALYN A · CIK 0001405288 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,551

F1 · kind: Represents a grant of restricted stock units which vest on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.

SEC source: 0001628280-26-044290 · wk-form4_1781813560.xml · derivative · entry 2

Brennan Daniel J. · CIK 0001595612 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 681

Underlying: Common Stock · 681 shares

Expires 2036-06-17

F2 · derivative.exercise_date: The option vests as to 100% of underlying shares on the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's annual meeting of stockholders to be held in 2027, provided the Reporting Person continues in service with the Issuer on such date.